Expert Highlights Importance of Palliative Care in Surgical Oncology

News
Video

Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.

Palliative care may represent an important aspect of many surgical oncologists’ practices for patients with cancer, said Sean Dineen, MD.

In a conversation with CancerNetwork®, Dineen, an associate member in the Gastrointestinal Department, section leader for Peritoneal Disease, and the program director for the Complex General Surgical Oncology Fellowship at Moffitt Cancer Center, spoke about findings from a presentation he gave at the 2024 Society of Surgical Oncology Annual Meeting (SSO). In his session, he emphasized the use of palliative care in surgery to manage symptoms in patients.

During the presentation, Dineen tried to raise awareness of palliative care’s utility in this setting by describing examples from his practice. One procedure he highlighted involved removing symptomatic abdominal wall lesions to help alleviate pain.

Transcript:

The theme of the session overall was to try to help surgical oncologists understand what their role was, as surgeons, in the treatment of patients with advanced cancer and, in some instances, potentially at the end of life. The first session talked a little bit more about how to incorporate palliative care or supportive care into your practice. In my session, the talk that I gave was more focused specifically on how to use surgery and how to design, plan, and talk about operations that were intended to treat symptoms. That was the focus of what my talk was on: indications in which surgery may be beneficial to treat symptoms, even if it’s not necessarily intended to prolong survival.

There were a few take-home points. The first was to raise awareness of how important it is for surgical oncologists to understand palliative care and to understand the scope that it may play in their practice. In some reports, up to 40% of consults may be related to some form of symptom control or palliative-intent surgery. It could represent quite a big part of most surgical oncologists’ or many surgical oncologists’ practice. That was an important message for us to get across. The second was just some specific instances where surgery may be quite helpful at relieving symptoms. I gave examples from my practice of abdominal wall lesions that are symptomatic and can be painful that we will remove, as well as some adnexal or ovarian tumors that can become quite large and lead to bowel obstruction. Those were a couple of examples where we talked a little bit more specifically about the operation and what to expect from that.

Reference

Dineen S. The role of the surgeon in palliating cancer patients. Presented at the Society of Surgical Oncology (SSO) 2024 Annual Meeting; March 20-23, 2024; Atlanta, GA.

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.